1. Scrip
  2. >>Business
  3. >>Earnings

Skyrizi Launch Skyrockets, Boosting AbbVie Hopes For Humira Successors

 
• By Joseph Haas

AbbVie’s balancing act sees Skyrizi/Rinvoq launches and strong hematologic cancer strength offset the continued erosion of Humira sales outside the US. Rinvoq gets off to a quick start in its US launch.

Pebble tower on the seaside - Image
AbbVie is successfully balancing Humira's biosimilar erosion with new brand growth

Third quarter 2019 was one of balance for AbbVie Inc. as a continued strong launch for Skyrizi, good early uptake of Rinvoq, ongoing US sales growth for Humira and steadily rising sales for its hematological cancer franchise offset Humira’s revenue decline in Europe due to biosimilar competition.

The Chicago-area firm reported quarterly net revenues of $8.5bn on 1 November, up 3% year-over-year, as its two new immunology drugs and its hematology products more than made up for a 33

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.